Skip to content

Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk

Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05045235
Acronym
IATROPREV
Enrollment
1500
Registered
2021-09-16
Start date
2021-09-01
Completion date
2025-12-31
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Consultation, Follow-up, Iatrogenic Effect, Prescription

Keywords

iatrogenic, prescription, follow-up, consultation

Brief summary

The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patient hospitalized in the geriatric medicine department * Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization; * Numerous therapeutic modifications (3 or more); * Drug interaction or introction of a new drug with one or more drug interactions; * Medicinal product with a narrow therapeutic marge drug requiring close monitoring.

Exclusion criteria

* patient non hospitalized in the geriatric medicine department

Design outcomes

Primary

MeasureTime frameDescription
Change of side effect number in ederly with polymedicated drugsup to 4 yearsChange of side effect number in ederly with polymedicated drugs

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026